Rhumbline Advisers Avalo Therapeutics, Inc. Transaction History

Rhumbline Advisers

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.0 - $10.45 $149,184 - $519,657	-49,728 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$7.57 - $21.72 $19,182 - $55,038	2,534 Added 5.37%	49,728 $36,000
Q4 2021 Feb 10, 2022	SELL	$19.68 - $28.68 $4,014 - $5,850	-204 Reduced 0.43%	47,194 $80,000
Q3 2021 Nov 12, 2021	BUY	$26.16 - $40.68 $1.24 Million - $1.93 Million	47,398 New	47,398 $103,000

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $118M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.